![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
QDMRK, A Phase III Study of the Safety & Efficacy of Once Daily (QD) Versus Twice Daily (BID) Raltegravir (RAL) in Combination Therapy for Treatment-Naïve HIV-Infected Patients (Pts)
|
|
|
Reported by Jules Levin
J. Eron1, J. Rockstroh2, J. Reynes3, J. Andrade4, J. Madruga5, J. Zhao6, P. Sklar6, B-Y. Nguyen6 for the QDMRK Study Team
1Univ. of North Carolina, Chapel Hill, NC, USA; 2Univ. of Bonn, Bonn-Venusberg, Germany; 3Montpellier Univ. Hospital, Montpellier, France; 4Universidad de Guadalajara, Mexico; 5Centro de Referencia DST/AIDS, Sao Paulo, Brazil and 6Merck Research Laboratories, North Wales, PA, USA
![apasl1.gif](../images/030911/030911-1/apasl1.gif)
![apasl2.gif](../images/030911/030911-1/apasl2.gif)
![apasl3.gif](../images/030911/030911-1/apasl3.gif)
![apasl4.gif](../images/030911/030911-1/apasl4.gif)
![apasl5.gif](../images/030911/030911-1/apasl5.gif)
![apasl6.gif](../images/030911/030911-1/apasl6.gif)
![apasl7.gif](../images/030911/030911-1/apasl7.gif)
![apasl8.gif](../images/030911/030911-1/apasl8.gif)
![apasl9.gif](../images/030911/030911-1/apasl9.gif)
![apasl10.gif](../images/030911/030911-1/apasl10.gif)
![apasl11.gif](../images/030911/030911-1/apasl11.gif)
![apasl12.gif](../images/030911/030911-1/apasl12.gif)
![apasl13.gif](../images/030911/030911-1/apasl13.gif)
![apasl14.gif](../images/030911/030911-1/apasl14.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|